JP2019528693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528693A5 JP2019528693A5 JP2019510849A JP2019510849A JP2019528693A5 JP 2019528693 A5 JP2019528693 A5 JP 2019528693A5 JP 2019510849 A JP2019510849 A JP 2019510849A JP 2019510849 A JP2019510849 A JP 2019510849A JP 2019528693 A5 JP2019528693 A5 JP 2019528693A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- amino acid
- peptide
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 34
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 230000002265 prevention Effects 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 229940122985 Peptide agonist Drugs 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 claims 5
- 101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 claims 5
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 241000283070 Equus zebra Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000000763 Survivin Human genes 0.000 claims 3
- 108010002687 Survivin Proteins 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 1
- 101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 claims 1
- 101000801539 Homo sapiens Mitochondrial import receptor subunit TOM34 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 1
- 102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 102100033583 Mitochondrial import receptor subunit TOM34 Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2016/072475 | 2016-09-21 | ||
| EP2016072475 | 2016-09-21 | ||
| PCT/EP2017/073954 WO2018055060A1 (en) | 2016-09-21 | 2017-09-21 | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528693A JP2019528693A (ja) | 2019-10-17 |
| JP2019528693A5 true JP2019528693A5 (enExample) | 2020-11-05 |
| JP7346291B2 JP7346291B2 (ja) | 2023-09-19 |
Family
ID=60037562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510849A Active JP7346291B2 (ja) | 2016-09-21 | 2017-09-21 | 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190255165A1 (enExample) |
| EP (1) | EP3515476B1 (enExample) |
| JP (1) | JP7346291B2 (enExample) |
| KR (2) | KR102879364B1 (enExample) |
| CN (1) | CN109963585B (enExample) |
| AU (1) | AU2017331949B2 (enExample) |
| CA (1) | CA3031170A1 (enExample) |
| CL (3) | CL2019000694A1 (enExample) |
| DK (1) | DK3515476T3 (enExample) |
| ES (1) | ES2983085T3 (enExample) |
| HU (1) | HUE067838T2 (enExample) |
| IL (1) | IL265479B (enExample) |
| MX (1) | MX2019002968A (enExample) |
| PL (1) | PL3515476T3 (enExample) |
| WO (1) | WO2018055060A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| ES2977541T3 (es) | 2016-03-16 | 2024-08-26 | Amal Therapeutics Sa | Combinación de modulador de puntos de control inmunitarios y complejo que comprende un péptido de penetracióncelular, una molécula de carga y un agonista peptídico de TLR para su uso en medicina |
| IL265479B (en) | 2016-09-21 | 2022-09-01 | Amal Therapeutics Sa | A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy |
| AU2018250226B2 (en) | 2017-04-04 | 2025-04-24 | Barinthus Biotherapeutics North America, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| US12121573B2 (en) | 2019-07-14 | 2024-10-22 | Tianxin Wang | Methods and agents including STING agonist to treat tumor |
| US11945850B2 (en) * | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| US20230000960A1 (en) * | 2019-06-12 | 2023-01-05 | Biontech Us Inc. | Neoantigen compositions and uses thereof |
| CN110448689A (zh) * | 2019-08-06 | 2019-11-15 | 太仓美诺恒康生物技术有限公司 | mRNA疫苗及其试剂盒、应用 |
| WO2021102215A1 (en) * | 2019-11-22 | 2021-05-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for increasing transduction efficiency with cell membrane fusion proteins |
| EP3827840A1 (en) * | 2019-11-29 | 2021-06-02 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Teipp peptide variant and uses thereof |
| KR20230012559A (ko) | 2020-05-19 | 2023-01-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 결합 분자 |
| CR20230155A (es) * | 2020-09-14 | 2023-06-27 | Boehringer Ingelheim Int | Vacuna heteróloga de estímulo primario |
| JP2023545178A (ja) * | 2020-10-14 | 2023-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ |
| CN113480666B (zh) * | 2021-08-13 | 2024-01-26 | 郑州伊美诺生物技术有限公司 | Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 |
| CN113786481A (zh) * | 2021-09-27 | 2021-12-14 | 深圳市中佳生物医疗科技有限公司 | 一种抗肿瘤疫苗及其制备方法 |
| AR128799A1 (es) * | 2022-03-16 | 2024-06-12 | Boehringer Ingelheim Int | Antígenos tumorales, compuestos que comprenden los antígenos tumorales y usos de los mismos |
| KR102823824B1 (ko) | 2022-08-10 | 2025-06-24 | 강원대학교산학협력단 | Pde5 억제제 특이적 결합 도메인, 재조합 단백질 및 이의 용도 |
| KR102886457B1 (ko) | 2022-10-14 | 2025-11-18 | 강원대학교산학협력단 | mTOR 억제제 특이적 결합 도메인, 재조합 단백질 및 이의 용도 |
| GB202216453D0 (en) * | 2022-11-04 | 2022-12-21 | Lisziewicz Julianna | Identification of antigens which induce t-cell responses |
| WO2024196664A1 (en) * | 2023-03-17 | 2024-09-26 | University Of Washington | Dna vaccine targeting overexpressed antigens in colorectal cancer |
| WO2025009503A1 (ja) * | 2023-07-03 | 2025-01-09 | メスキュージェナシス株式会社 | 細胞膜透過性を有するペプチドおよびそのスクリーニング方法 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| FR2728904B1 (fr) | 1995-01-04 | 1997-03-14 | Pasteur Institut | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| SI1141028T1 (sl) | 1998-12-23 | 2010-05-31 | Pfizer | Človeška monoklonska protitelesa proti CTLA |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP4093757B2 (ja) | 1999-08-24 | 2008-06-04 | メダレックス， インコーポレイテッド | ヒトｃｔｌａ−４抗体およびその使用 |
| US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
| AU2001256156B2 (en) * | 2000-02-23 | 2006-01-05 | Smithkline Beecham Biologicals S.A. | Novel compounds |
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| AUPR593101A0 (en) | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| GB0218821D0 (en) | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| MXPA05004022A (es) | 2002-10-17 | 2005-10-05 | Genmab As | Anticuerpos monoclonales humanos contra cd20. |
| US20090311279A1 (en) | 2003-10-15 | 2009-12-17 | National Institutes Of Health | Colorectal Cancer Antigen |
| EP1768698A4 (en) | 2004-06-17 | 2009-01-28 | Medimmune Inc | IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| EP2329840A1 (en) | 2005-02-04 | 2011-06-08 | Survac ApS | Survivin peptide vaccine |
| ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| NZ594510A (en) | 2006-12-27 | 2012-06-29 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| HRP20150820T1 (xx) | 2007-07-27 | 2015-09-11 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv neuronskih tumora i tumora mozga |
| WO2009018500A1 (en) | 2007-07-31 | 2009-02-05 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| BRPI0911604A2 (pt) | 2008-04-25 | 2015-12-15 | Inst Systems Biology | vacinas de polipeptídeo de flagelina |
| EP2119726B2 (en) | 2008-05-14 | 2017-11-29 | Immatics Biotechnologies GmbH | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| EP3156069B8 (en) | 2008-06-20 | 2020-10-21 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR101040281B1 (ko) * | 2008-08-22 | 2011-06-10 | 가톨릭대학교 산학협력단 | Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
| US8074880B2 (en) | 2008-12-01 | 2011-12-13 | Research In Motion Limited | Method, system and mobile device employing enhanced fingerprint authentication |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| WO2010105347A1 (en) | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
| PE20120400A1 (es) * | 2009-05-27 | 2012-05-04 | Glaxosmithkline Biolog Sa | Contrucciones de casb7439 |
| EA201270228A1 (ru) | 2009-07-31 | 2012-09-28 | Медарекс, Инк. | Полноценные человеческие антитела к btla |
| JP2013503204A (ja) | 2009-08-31 | 2013-01-31 | アンプリミューン， インコーポレイテッド | Ｂ７−ｈ４融合タンパク質およびその使用方法 |
| WO2011029980A1 (es) | 2009-09-11 | 2011-03-17 | Proyecto De Biomedicina Cima, S.L. | Composiciones terapéuticas para el tratamiento de enfermedades causadas por hpv |
| WO2011036211A1 (en) | 2009-09-23 | 2011-03-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptides and nucleic acids for treating erbb2-dependent cancers |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011135222A2 (fr) | 2010-04-26 | 2011-11-03 | Universite Joseph Fourier | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles |
| US9314516B2 (en) | 2010-05-04 | 2016-04-19 | Cassian Yee | Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses |
| US8968746B2 (en) | 2010-07-30 | 2015-03-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| ES2930809T3 (es) | 2010-08-24 | 2022-12-22 | Univ Pittsburgh Commonwealth Sys Higher Education | Vacunas contra el cáncer cerebral basadas en el péptido receptor de interleucina-13 alfa 2 |
| EP2616098B1 (en) | 2010-09-14 | 2016-04-20 | Council of Scientific & Industrial Research | A synthetic immunogen useful for generating long lasting immunity and protection against pathogens |
| WO2012048190A1 (en) | 2010-10-08 | 2012-04-12 | Regents Of The University Of Minnesota | Annexin ii compositions and methods |
| KR101760464B1 (ko) | 2010-10-13 | 2017-07-24 | 사회복지법인 삼성생명공익재단 | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 |
| JP6041444B2 (ja) | 2011-01-10 | 2016-12-07 | クリーブランド バイオラブズ，インコーポレイテッド | 癌を治療するためのＴｏｌｌ様受容体アゴニストの使用 |
| US9187534B2 (en) * | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| US8795678B2 (en) | 2011-05-13 | 2014-08-05 | Academia Sinica | TLR-2 agonists and methods of use thereof |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
| ES2861435T3 (es) | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas |
| HK1202252A1 (en) | 2011-11-16 | 2015-09-25 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant viii related disorders |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| US9597393B2 (en) | 2012-02-09 | 2017-03-21 | Av Therapeutics, Inc. | Synthetic toll-like receptor-4 (TLR-4) agonist peptides |
| CN104487083B (zh) * | 2012-07-13 | 2018-11-20 | S-目标疗法有限公司 | 免疫调节疫苗 |
| WO2014165101A1 (en) | 2013-03-13 | 2014-10-09 | California Stem Cell, Inc. | Individualized high purity colon carcinoma stem cells, methods and use of the same |
| WO2014041505A1 (en) | 2012-09-13 | 2014-03-20 | Universite De Geneve | Cell penetrating peptides |
| SG11201501850VA (en) | 2012-09-21 | 2015-04-29 | Intensity Therapeutics Inc | Method of treating cancer |
| US20150290306A1 (en) | 2012-10-29 | 2015-10-15 | David E. Anderson | Compositions and methods for diagnosis and treatment of malignant gliomas |
| CA2929651A1 (en) | 2013-11-06 | 2015-05-14 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
| ES2928331T3 (es) * | 2013-11-13 | 2022-11-17 | Univ Minnesota | Composiciones de variantes de anexina II y métodos |
| SG10201805674YA (en) | 2014-01-02 | 2018-08-30 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| AU2015269053A1 (en) | 2014-06-06 | 2016-12-22 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| RU2739794C2 (ru) * | 2014-10-31 | 2020-12-28 | Массачусетс Инститьют Оф Текнолоджи | Доставка биомолекул в клетки иммунной системы |
| KR20210069124A (ko) * | 2014-11-13 | 2021-06-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| WO2016146143A1 (en) * | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| BR102015025502B1 (pt) | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| WO2017002345A1 (ja) | 2015-06-29 | 2017-01-05 | パナソニックＩｐマネジメント株式会社 | 冷蔵庫 |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| DK3805376T3 (da) | 2016-01-08 | 2025-09-29 | Replimune Ltd | Modificeret virus |
| WO2017120670A1 (en) | 2016-01-11 | 2017-07-20 | Brian Lichty | Oncolytic virus and checkpoint inhibitor combination therapy |
| ES2977541T3 (es) | 2016-03-16 | 2024-08-26 | Amal Therapeutics Sa | Combinación de modulador de puntos de control inmunitarios y complejo que comprende un péptido de penetracióncelular, una molécula de carga y un agonista peptídico de TLR para su uso en medicina |
| EP3455350A4 (en) | 2016-05-09 | 2020-01-15 | Turnstone Limited Partnership | PRIMO-VACCINATION / RECALL POLYTHERAPY |
| PL417980A1 (pl) | 2016-07-16 | 2018-01-29 | Univ Warszawski | Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu |
| US11052149B2 (en) | 2016-09-19 | 2021-07-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
| IL265479B (en) * | 2016-09-21 | 2022-09-01 | Amal Therapeutics Sa | A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| JP2021512104A (ja) | 2018-02-02 | 2021-05-13 | ノバルティス アーゲー | 癌の治療のためのＳＴＩＮＧアゴニスト及びＩＬ−１５／ＩＬ１５−Ｒａの組合せ |
| WO2019246450A1 (en) | 2018-06-20 | 2019-12-26 | Yale University | Rig-i agonists and treatments using same |
| WO2020010451A1 (en) | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| CR20230155A (es) | 2020-09-14 | 2023-06-27 | Boehringer Ingelheim Int | Vacuna heteróloga de estímulo primario |
| JP2023545178A (ja) * | 2020-10-14 | 2023-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ |
-
2017
- 2017-09-21 IL IL265479A patent/IL265479B/en unknown
- 2017-09-21 US US16/331,398 patent/US20190255165A1/en not_active Abandoned
- 2017-09-21 DK DK17780656.9T patent/DK3515476T3/da active
- 2017-09-21 MX MX2019002968A patent/MX2019002968A/es unknown
- 2017-09-21 JP JP2019510849A patent/JP7346291B2/ja active Active
- 2017-09-21 ES ES17780656T patent/ES2983085T3/es active Active
- 2017-09-21 PL PL17780656.9T patent/PL3515476T3/pl unknown
- 2017-09-21 AU AU2017331949A patent/AU2017331949B2/en active Active
- 2017-09-21 KR KR1020237029678A patent/KR102879364B1/ko active Active
- 2017-09-21 HU HUE17780656A patent/HUE067838T2/hu unknown
- 2017-09-21 CN CN201780069631.0A patent/CN109963585B/zh active Active
- 2017-09-21 WO PCT/EP2017/073954 patent/WO2018055060A1/en not_active Ceased
- 2017-09-21 EP EP17780656.9A patent/EP3515476B1/en active Active
- 2017-09-21 KR KR1020197011382A patent/KR20190057345A/ko not_active Ceased
- 2017-09-21 CA CA3031170A patent/CA3031170A1/en active Pending
-
2019
- 2019-03-18 CL CL2019000694A patent/CL2019000694A1/es unknown
-
2020
- 2020-11-25 US US17/104,786 patent/US11338027B2/en active Active
-
2021
- 2021-06-11 CL CL2021001541A patent/CL2021001541A1/es unknown
-
2022
- 2022-04-12 US US17/718,975 patent/US12220387B2/en active Active
-
2023
- 2023-07-31 CL CL2023002252A patent/CL2023002252A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528693A5 (enExample) | ||
| JP2018509936A5 (enExample) | ||
| JP2018510215A5 (enExample) | ||
| AU2020201896B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| AU2016368433B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| AU2022268324B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| HRP20200491T1 (hr) | Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma | |
| AR121588A2 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| ES2833162T3 (es) | Receptor de antígeno quimérico y su uso | |
| TW201841934A (zh) | 用於治療癌症免疫治療的新穎肽及其肽組合物 | |
| PE20240778A1 (es) | Nuevos peptidos y combinacion de peptidos para usar en inmuterapia contra el cancer esofagico y otros canceres | |
| US20250312428A1 (en) | Heterologous Prime Boost Vaccine | |
| AU2022204032B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| Belnoue et al. | Enhancing antitumor immune responses by optimized combinations of cell-penetrating peptide-based vaccines and adjuvants | |
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
| MY166516A (en) | Tomm34 peptides and vaccines including the same | |
| MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
| V. Savvateeva et al. | Prophylactic admission of an in vitro reconstructed complexes of human recombinant heat shock proteins and melanoma antigenic peptides activates anti-melanoma responses in mice | |
| JP2013540419A5 (enExample) | ||
| MX2013004417A (es) | Peptidos wdhd1 y vacunas que los incluyen. | |
| JP2017500305A5 (enExample) | ||
| CN108929867B (zh) | 抗肿瘤的多肽及其制备方法和应用 | |
| US20180028630A1 (en) | Compositions and methods for therapeutic anti-cancer vaccination | |
| Li | Role of heat shock protein in chaperoning tumor antigens and modulating anti-tumor immunity | |
| NZ746513A (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors |